Related Experiment Videos
Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.
N Baldini1, K Scotlandi, M Serra
1Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy.
Journal of Cancer Research and Clinical Oncology
|January 1, 1992
Summary
The Adriamycin binding assay (ABA) reliably predicts osteosarcoma sensitivity by evaluating drug uptake patterns. ABA detects resistance, even when P-glycoprotein levels are normal, aiding clinical treatment decisions.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Osteosarcoma treatment often relies on Adriamycin, but drug resistance limits efficacy.
- Predicting patient response to Adriamycin is crucial for effective treatment strategies.
Purpose of the Study:
- To evaluate the reliability of the Adriamycin binding assay (ABA) as an index of drug sensitivity in human osteosarcoma.
- To compare ABA results with P-glycoprotein expression in sensitive and resistant cell lines.
Main Methods:
- Primary cultures and cell lines of human osteosarcoma were used.
- Cells were exposed to Adriamycin (10 µg/ml for 30 min at 37°C).
- Subcellular Adriamycin distribution was analyzed, and P-glycoprotein expression was assessed.
Main Results:
- Sensitive cells showed selective intranuclear Adriamycin uptake, while resistant cells did not.
- Adriamycin binding patterns inversely correlated with P-glycoprotein expression in highly resistant cells.
- ABA identified low-level in vitro resistance not detectable by P-glycoprotein expression alone.
Conclusions:
- The Adriamycin binding assay (ABA) is a reliable method for assessing osteosarcoma sensitivity to Adriamycin.
- Combining ABA with P-glycoprotein assessment improves the prediction of Adriamycin sensitivity in clinical practice.